952569-82-3

Upstream product

• 952569-81-2 4-chloro-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 
• 16631-18-8 diethyl 2-methylacetonedicarboxylate 
• 853106-90-8 ethyl 4-hydroxy-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 853109-70-3 ethyl 4-chloro-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate 

Downstream Products

• 952569-83-4 1-(2-fluoro-4-iodophenyl)-5,7-dimethyl-1-imidazo[4,5-c]pyridine-2,6(3H,5H)-dione 

Relevant academic research and scientific papers

BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administred to a Hepatocellu

PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS

This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.